Featured Articles
-
Navigating Growth In Biotech: A First-Person Insight
4/19/2024
Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value.
-
Michigan No Longer A Safe Haven For Pharmaceutical Companies?
4/17/2024
A recent change to Michigan's product liability law could have national implications. Experts at Sidley Austin detail the changes in Michigan, and explain what it could mean for pharmaceutical companies marketing products in Michigan and beyond.
-
Continuing Down The Road To BioPharma Board Diversification
4/12/2024
Diversification in the boardroom improves the quality of board performance, encourages objectivity, and expands the quality of debate and decision making. Biopharmaceutical industry boardrooms are making progress, but still have work to do.
-
Delivering The Next Evolution In Immuno-Oncology
4/9/2024
To continue the momentum created by new discoveries and treatments for cancer patients, drug developers need a strong and focused corporate culture, employees willing to challenge established norms, and a system for prioritizing development candidates guided by science and patient needs.
-
Start Fast, Finish Fast: How To Complete Projects On Time
4/5/2024
Teams often do a brilliant job executing during the middle of projects. Once a project has been defined and it gains momentum, the project moves along rapidly, until it is time for final deliverables. Ken Ford offers advice for expediting the beginning and the end of projects.
-
Small Startup Going For A Big Play In Obesity
3/29/2024
Can a small startup compete on the big obesity stage? Resalis hopes to bring a new mechanism, and new benefits, to the fight against obesity.
-
A View From The Co-Chair Of Israel’s Biopharma Industry Trade Organization
3/28/2024
Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.
-
Leveraging Fractional Expertise to Drive Project Success and Cost Savings
3/27/2024
Life sciences companies in need of expertise on a budget can take advantage of the gig economy to hire high quality "fractional" talent for specific projects, in lieu of new full-time employees.
-
Examining The Growth Of Biopharma In Developing Countries
3/26/2024
Support from local governments and renewed interest from biopharmaceutical companies are coalescing to drive growth in key developing markets.
-
Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
3/22/2024
AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.